These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. INFERENCE OF PERSONALIZED DRUG TARGETS VIA NETWORK PROPAGATION. Shnaps O; Perry E; Silverbush D; Sharan R Pac Symp Biocomput; 2016; 21():156-67. PubMed ID: 26776182 [TBL] [Abstract][Full Text] [Related]
5. REDESIGN: RDF-based Differential Signaling Framework for Precision Medicine Analytics. Al-Taie Z; Thanintorn N; Ersoy I; Kholod O; Taylor K; Hammer R; Shin D AMIA Jt Summits Transl Sci Proc; 2018; 2017():35-44. PubMed ID: 29888036 [TBL] [Abstract][Full Text] [Related]
6. Functional Analysis of OMICs Data and Small Molecule Compounds in an Integrated "Knowledge-Based" Platform. Dubovenko A; Nikolsky Y; Rakhmatulin E; Nikolskaya T Methods Mol Biol; 2017; 1613():101-124. PubMed ID: 28849560 [TBL] [Abstract][Full Text] [Related]
7. Biomarkers for personalized oncology: recent advances and future challenges. Kalia M Metabolism; 2015 Mar; 64(3 Suppl 1):S16-21. PubMed ID: 25468140 [TBL] [Abstract][Full Text] [Related]
8. Mapping the protein-protein and genetic interactions of cancer to guide precision medicine. Bouhaddou M; Eckhardt M; Chi Naing ZZ; Kim M; Ideker T; Krogan NJ Curr Opin Genet Dev; 2019 Feb; 54():110-117. PubMed ID: 31288129 [TBL] [Abstract][Full Text] [Related]
10. An integrated framework for reporting clinically relevant biomarkers from paired tumor/normal genomic and transcriptomic sequencing data in support of clinical trials in personalized medicine. Nasser S; Kurdolgu AA; Izatt T; Aldrich J; Russell ML; Christoforides A; Tembe W; Keifer JA; Corneveaux JJ; Byron SA; Forman KM; Zuccaro C; Keats JJ; Lorusso PM; Carpten JD; Trent JM; Craig DW Pac Symp Biocomput; 2015; ():56-67. PubMed ID: 25592568 [TBL] [Abstract][Full Text] [Related]
11. A multiple network-based bioinformatics pipeline for the study of molecular mechanisms in oncological diseases for personalized medicine. Dotolo S; Marabotti A; Rachiglio AM; Esposito Abate R; Benedetto M; Ciardiello F; De Luca A; Normanno N; Facchiano A; Tagliaferri R Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 34050359 [TBL] [Abstract][Full Text] [Related]
12. KNOWLEDGE DRIVEN BINNING AND PHEWAS ANALYSIS IN MARSHFIELD PERSONALIZED MEDICINE RESEARCH PROJECT USING BIOBIN. Basile AO; Wallace JR; Peissig P; McCarty CA; Brilliant M; Ritchie MD Pac Symp Biocomput; 2016; 21():249-60. PubMed ID: 26776191 [TBL] [Abstract][Full Text] [Related]
13. Molecular network analysis of diseases and drugs in KEGG. Kanehisa M Methods Mol Biol; 2013; 939():263-75. PubMed ID: 23192552 [TBL] [Abstract][Full Text] [Related]
14. [Aiming for zero blindness]. Nakazawa T Nippon Ganka Gakkai Zasshi; 2015 Mar; 119(3):168-93; discussion 194. PubMed ID: 25854109 [TBL] [Abstract][Full Text] [Related]
15. Chronic myelogenous leukemia as a paradigm of early cancer and possible curative strategies. Clarkson B; Strife A; Wisniewski D; Lambek CL; Liu C Leukemia; 2003 Jul; 17(7):1211-62. PubMed ID: 12835715 [TBL] [Abstract][Full Text] [Related]
16. Precision Medicine Intelligence - evidence scoring evaluating the clinical actionability of BRAF V600E in multiple non-melanoma solid tumors. Crescenzo A Drugs Today (Barc); 2016 Jul; 52(7):399-405. PubMed ID: 27540599 [TBL] [Abstract][Full Text] [Related]
17. Functional analysis of OMICs data and small molecule compounds in an integrated "knowledge-based" platform. Nikolsky Y; Kirillov E; Zuev R; Rakhmatulin E; Nikolskaya T Methods Mol Biol; 2009; 563():177-96. PubMed ID: 19597786 [TBL] [Abstract][Full Text] [Related]
18. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia. Steinberg M Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072 [TBL] [Abstract][Full Text] [Related]
19. PATIENT-SPECIFIC DATA FUSION FOR CANCER STRATIFICATION AND PERSONALISED TREATMENT. Gligorijević V; Malod-Dognin N; Pržulj N Pac Symp Biocomput; 2016; 21():321-32. PubMed ID: 26776197 [TBL] [Abstract][Full Text] [Related]
20. Cellular Mechanisms Underlying Complete Hematological Response of Chronic Myeloid Leukemia to BRAF and MEK1/2 Inhibition in a Patient with Concomitant Metastatic Melanoma. Andrews MC; Turner N; Boyd J; Roberts AW; Grigg AP; Behren A; Cebon J Clin Cancer Res; 2015 Dec; 21(23):5222-34. PubMed ID: 26202951 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]